The stock market has taken some hits so far in 2022, but this move lower has opened up opportunities to buy up high-quality stocks at discount prices.And there are 3 undervalued stocks to buy this week that can outperform over the years to come.
Category
Biotech Stocks
Insider Buying Detected – Buy This Biotech Now
Garrett Baldwin picks out the best biotech stock to buy right now.
This Must-Buy Biotech Firm Makes Over Double Pfizer’s Profits
Shah Gilani picks out the best biotech stock to buy right now.
It’s a no-brainer, folks. Check out this video for the ticker and two bonus trades…
How to Trade Pfizer Stock for a 290% Profit in a Month
Pfizer's recent news that their COVID-19 vaccine is 90% effective sent the market (and Pfizer's stock) soaring.
And while those who had already invested in the stock have made a nice return, Tom's going to show you the quick and easy way to almost quadruple your money on it…
Instead of Chasing Every New Vaccine "Breakthrough," Trade the Whole Sector
Not every biotech company is doing well in the search for an effective COVID-19 vaccine or treatment.
And the latest firm to struggle is Eli Lilly, whose antibody clinical trial was paused due to failure to show any real results.
So today, Andrew's going to show you a much more profitable move to make instead of chasing every vaccine "breakthrough" news…
This Biotech Has Delivered 1,000% in Profits So Far; Here’s What’s Next
One perfectly positioned biotech Don’s going to tell you about today is close to hitting the crucial $1 billion threshold.
It hasn’t happened yet, but when it does, they’ll have done it faster than the likes of Apple or Google.
And if you’re finding out about it now, you’re just in time because the setup looks very promising.
But you’ll have to act fast, and grab the shares before Wall Street finds out about it….
The Incredible Technology Saving Critically Ill COVID-19 Patients
One of the starkest lessons of the global novel coronavirus pandemic is the need for medicine to start looking at existing drugs and procedures in a new way.
We've already seen the benefits of such an approach. The discovery that remdesivir and dexamethasone – an antiviral and a steroid – could both help save severely ill COVID-19 patients' lives springs right to mind.
But adapting the old to fight the new isn't just limited to drugs. Existing medical technology ("medtech") is being used in entirely new ways, or in situations that would've been unthinkable just 10 or 12 months ago.
That's why today I want to talk to you about two compelling companies behind a radical, aggressive therapy that can deliver a "one-two punch" for coronavirus patients who might've otherwise died… Full Story
Buy This "Post-COVID America" Money-Doubler at a Great Discount
The best minds in biotech are working round the clock to put a stop to the COVID-19 pandemic. The project includes over 135 vaccine candidates, and the profit potential here is massive.
This is literally about saving the world.
The thing is, though, vaccines are only one part of this project. There's another dimension, a "silent partner" in the project, that doesn't get quite so much heroic headline ink but is just as important.
You see, of all the vaccines coming down the pipeline, 31 are currently in human trials. There's a very good chance that one of them will be safe and powerful enough to begin mass distribution in early 2021.
But there are 328 million living Americans and 7.5 billion humans on planet earth. It will take time to vaccinate them all, and that's where our "silent partner" comes in.
It's blazing a trail towards the kind of better COVID-19 testing technology we will need to get things fully back to normal.
And not only that – it's on a solid track to double your money in just two years… Full Story
And not only that - it's on a solid track to double your money in just two years...
Profit on This Biotech-Enabler That’s Suddenly a “Buy”
"Lead, follow, or get out of the way."
This is one of those well-known aphorisms that's been around forever – though its originator is unknown.
Truth be told, it doesn't matter who said it first. It's a great bit of advice.
Especially as we interpret it.
In our investment work here at Money Morning, we always seek to lead Wall Street and the rest of the packrat investment crowd.
We never follow, especially since "the crowd" tends to be indecisive, late to the gun – or flat out wrong.
And we always get out of the way – sidestepping the dust-rising thump that's an inevitable result of the miscues and sins of the Wall Street Goliath.
It's a simple formula. And a successful one.
And it's the reason we keep outperforming "the crowd."
Like the 2,067% gain on biotech Galapagos NV, the very first stock I recommended on the very first day I published my Member-based service, Private Briefing, back in August 2011.
My readers also pulled down peak gains of more than 2,892% in Nvidia, 2,828% in Advanced Micro Devices, 818% in biotech buyout Pharmacyclics, and more.
Today, I've decided to share my latest insight on one of my big biotech winners with Money Morning readers because the opportunity is too good to keep to ourselves. And since my colleague Michael Robinson recently talked about 2020's record-crushing biotech IPOs, it's the perfect time to share this.
The company I'm showing you today is essential to biotech stocks. It's a "biotech-enabler" that's zoomed 1,755% since I first told my readers about it back in June 2013.
In 2013, it was trading at $8.14.
It closed July 30 at $151.25 – not long after Investor's Business Daily said the stock had entered a "Buy Zone."
True, but where were they seven years and 1,755% ago?
Of course, what's important now is what comes next – and it's clear this stock's run isn't over… Full Story
Biotech (and Its IPOs) Will Crush Records in 2020 - Here's How to Profit
I'll come right out and say it: Every investor should be doing their level best to position themselves at the epicenter of biotechnology – pharmaceuticals – right now.
These stocks are leading a soaring stock market, particularly the NASDAQ Composite, which is at all-time highs. Of the index's 10 biggest gainers at midday yesterday, half were biotechs.
Obviously, the race to find a vaccine or even a proven therapy for the novel coronavirus pandemic is a huge driver of the profits here. My paid subscribers recently got the chance to book 375% gains on half of one of our vaccine research plays, and took 70% in profits on another.
But there's much more going on.
The sheer amount and volume of capital pouring into this sector like a firehose – it's nothing short of breathtaking.
I'm going to show you my favorite, low-risk way to tap that immense growth.
But first, you have to see some of these numbers… Full Story
But first, you have to see some of these numbers...